• Banner

  • Reduced price
Pharmaceutical Innovation: Challenges & Competitors

Pharmaceutical Innovation: Challenges & Competitors

9781622570683
661,44 zł
595,29 zł Save 66,15 zł Tax included
Lowest price within 30 days before promotion: 595,29 zł
Quantity
Available in 4-6 weeks

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DHL, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Description
Congress has exhibited a strong and ongoing interest in facilitating the development of new, innovative pharmaceuticals for the marketplace while reducing the cost of drugs to consumers. Policies pertaining to funding for research and development (R&D), intellectual property protection, and co-operative ventures have played an important role in the economic success of the pharmaceutical sector. Industry-specific legislation, also work to encourage innovation in the pharmaceutical sector while facilitating the entry of lower cost generic competition. While many factors contribute to innovation in the brand pharmaceutical industry and its ability to bring new and inventive products to the marketplace, this sector is facing significant issues associated with loss of revenue for additional R&D due to patent expirations and generic competition. This book examines the challenges associated with striking the proper balance between lower cost drugs and maintaining an innovative domestic pharmaceutical sector.
Product Details
73946
9781622570683
9781622570683

Data sheet

Rok wydania
2012
Numer wydania
1
Oprawa
twarda
Liczba stron
135
Wymiary (mm)
155.00 x 230.00
Waga (g)
370
  • Preface; Drug Patent Expirations:: Potential Effects on Pharmaceutical Innovation; Authorized Generic Pharmaceuticals:: Effects on Innovation; Pharmaceutical Patent Litigation Settlements:: Implications for Competition & Innovation; The Hatch-Waxman Act:: A Quarter Century Later; Follow-On Biologics:: The Law and Intellectual Property Issues; Index.
Comments (0)